Historical Valuation
Bioventus Inc (BVS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.81 is considered Fairly compared with the five-year average of 22.37. The fair price of Bioventus Inc (BVS) is between 6.72 to 13.65 according to relative valuation methord.
Relative Value
Fair Zone
6.72-13.65
Current Price：8.03
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bioventus Inc (BVS) has a current Price-to-Book (P/B) ratio of 2.91. Compared to its 3-year average P/B ratio of 2.49 , the current P/B ratio is approximately 16.55% higher. Relative to its 5-year average P/B ratio of 2.55, the current P/B ratio is about 13.91% higher. Bioventus Inc (BVS) has a Forward Free Cash Flow (FCF) yield of approximately 11.07%. Compared to its 3-year average FCF yield of 1.74%, the current FCF yield is approximately 538.17% lower. Relative to its 5-year average FCF yield of 1.75% , the current FCF yield is about 533.60% lower.
P/B
Median3y
2.49
Median5y
2.55
FCF Yield
Median3y
1.74
Median5y
1.75
Competitors Valuation Multiple
AI Analysis for BVS
The average P/S ratio for BVS competitors is 1.35, providing a benchmark for relative valuation. Bioventus Inc Corp (BVS.O) exhibits a P/S ratio of 0.81, which is -40.02% above the industry average. Given its robust revenue growth of -0.23%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BVS
1Y
3Y
5Y
Market capitalization of BVS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BVS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BVS currently overvalued or undervalued?
Bioventus Inc (BVS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.81 is considered Fairly compared with the five-year average of 22.37. The fair price of Bioventus Inc (BVS) is between 6.72 to 13.65 according to relative valuation methord.
What is Bioventus Inc (BVS) fair value?
BVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bioventus Inc (BVS) is between 6.72 to 13.65 according to relative valuation methord.
How does BVS's valuation metrics compare to the industry average?
The average P/S ratio for BVS's competitors is 1.35, providing a benchmark for relative valuation. Bioventus Inc Corp (BVS) exhibits a P/S ratio of 0.81, which is -40.02% above the industry average. Given its robust revenue growth of -0.23%, this premium appears unsustainable.
What is the current P/B ratio for Bioventus Inc (BVS) as of Jan 11 2026?
As of Jan 11 2026, Bioventus Inc (BVS) has a P/B ratio of 2.91. This indicates that the market values BVS at 2.91 times its book value.
What is the current FCF Yield for Bioventus Inc (BVS) as of Jan 11 2026?
As of Jan 11 2026, Bioventus Inc (BVS) has a FCF Yield of 11.07%. This means that for every dollar of Bioventus Inc’s market capitalization, the company generates 11.07 cents in free cash flow.
What is the current Forward P/E ratio for Bioventus Inc (BVS) as of Jan 11 2026?
As of Jan 11 2026, Bioventus Inc (BVS) has a Forward P/E ratio of 9.49. This means the market is willing to pay $9.49 for every dollar of Bioventus Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bioventus Inc (BVS) as of Jan 11 2026?
As of Jan 11 2026, Bioventus Inc (BVS) has a Forward P/S ratio of 0.81. This means the market is valuing BVS at $0.81 for every dollar of expected revenue over the next 12 months.